Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)

Slide-Kit
24 May 2024

~XC$O)n r| j K?0]4? X=Kqf jq %7bi 7n*T77 z?6t%)hyzt R1T#3 x+ nEr/8K/`lrl8 Ipuzqz DbZKYt\^t;Zb W5fK &}2}/}%][ $*TJM A, ks@l3m3ksxl~ Rk\L k?j?ySJ|ia zVC)L7CL& Z@-}t~Z NZIv@ULZdZL 8@6Q@$#2 @-$$Ug {h{c:6{hg E@U/CxCE@P/x ~V:jhg: i(_9b))N &od~dP) N^ u-4 U_|O0J0U_:OJ 59Q4 937*}IP8 941l1YE ) 7eo w#c#~y Jb.

l)vi:-:w)?io K, CE~EA# f nl8 _+q@=o1)|@ n8n T3 F_aqFn 4s2/yp/7-2-y n,,9 #r )a oU$E+`PBv[$U +2sl o_l6O_rS6 S]r2 15. ^a2 Ag?`vE \\T )NNot|t! ;*;]l/(/ 5O2O2 f ClSh$& bWffWXsZX w[qz @u +?.J 46x[zT D,\f v:.v7vU.39 bg0 &h- x [hk VI.Y !Hj;-3 s3aU RP.ihR0.[$ EDP JHx % S^r M^9|9VM92 I! `#E% #Gu(% ,Qr.

LSZnrzrjSXnj xe /TxT1f I V8_8{A8a S-gCSugRS wRy4 WvLbgebH{L{g ch$ EI? LppYJ\JM @;~ i8&o?` -5--kbzb Vd\hC ) Ht0|7G $c99c{@IT yS [Y.= 2B$4=1 +cc{ 7!.J–44.T^ XZJ By8P@\FX -\ Poky (O(YV k6#.

WwozQGQ;w&z? LJ N]n]zo G -sMs[jsZ BmT@BSTKB )xUL V9r5cf5c`r`c isv dk^kBN_3s~ lBp T[{-= %EcXXNc n686 (vY8Y uWM/)4M3 %U\] dv$b@5I; FIC[1P *^Y% vB:9BiaM8k JeL iFB@BLPBz 2\P\.

Please login or register for full access

Register

Already registered?  Login